1
|
Ulianskaite G, Timinskaite F, Raudonis T. Severe pityriasis rubra pilaris complicated with Kaposi's varicelliform eruption and cutaneous MRSA infection case report. Heliyon 2024; 10:e33750. [PMID: 39040271 PMCID: PMC11261859 DOI: 10.1016/j.heliyon.2024.e33750] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/03/2024] [Revised: 06/25/2024] [Accepted: 06/26/2024] [Indexed: 07/24/2024] Open
Abstract
A 62-year-old woman presented to our hospital with erythroderma affecting 100 % of body surface area, skin scaling and a body temperature of 37.3o C. The lesions initially appeared on her scalp 6 months prior, then psoriasis was diagnosed. Topical corticosteroids were prescribed, which were ineffective. After 2 months the rash spread to the rest of the body, accompanied by nail changes and hair loss. The patient was subsequently admitted to the local hospital, where following clinical evaluation, oral methotrexate 10 mg once weekly was initiated for 6 weeks. Despite the administered treatment the patient's health and skin condition deteriorated, manifesting with an appearance of new lesions. By the time of admission to our hospital erythroderma affecting 100 % of body surface area covered with wide skin scales and punched-out erosions on the torso, lower eyelid ectropion, loss of scalp hair and thickened yellow nail plates were observed. Skin biopsy revealed histological changes consistent with pityriasis rubra pilaris diagnosis. Polymerase chain reaction test from erosions confirmed the presence of herpes simplex virus 1/2 and culture results identified methicillin-resistant Staphylococcus aureus. Given the considerations of pityriasis rubra pilaris, hematologic disorders and paraneoplastic syndrome, a comprehensive work-up for haematological and oncological disorders was conducted, which yielded no significant findings. The patient was treated with intravenous corticosteroids, antibiotics, and antiviral drugs. Isotretinoin was initiated following the histological confirmation of pityriasis rubra pilaris. By the time of discharge, the patient's condition improved. During a follow-up visit 43 weeks after the initiation of isotretinoin, the skin was almost clear. The described case highlights the rare possibility of developing Kaposi's varicelliform eruption in patients with pityriasis rubra pilaris and demonstrates that isotretinoin is a safe and effective treatment option for this condition.
Collapse
Affiliation(s)
- Gintare Ulianskaite
- Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, LT-01513, Vilnius, Lithuania
| | | | - Tadas Raudonis
- Institute of Clinical Medicine, Faculty of Medicine, Vilnius University, LT-01513, Vilnius, Lithuania
| |
Collapse
|
2
|
Schmauch E, Severin Y, Xing X, Mangold A, Conrad C, Johannsen P, Kahlenberg JM, Mellett M, Navarini A, Nobbe S, Sarkar MK, Satyam A, Tsoi LC, French LE, Nilsson J, Linna-Kuosmanen S, Kaikkonen MU, Snijder B, Kellis M, Gudjonsson JE, Tsokos GC, Contassot E, Kolios AGA. Targeting IL-1 controls refractory pityriasis rubra pilaris. SCIENCE ADVANCES 2024; 10:eado2365. [PMID: 38959302 PMCID: PMC11221491 DOI: 10.1126/sciadv.ado2365] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/23/2024] [Accepted: 05/29/2024] [Indexed: 07/05/2024]
Abstract
Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disease with a poorly understood pathogenesis. Through a molecularly driven precision medicine approach and an extensive mechanistic pathway analysis in PRP skin samples, compared to psoriasis, atopic dermatitis, healed PRP, and healthy controls, we identified IL-1β as a key mediator, orchestrating an NF-κB-mediated IL-1β-CCL20 axis, including activation of CARD14 and NOD2. Treatment of three patients with the IL-1 antagonists anakinra and canakinumab resulted in rapid clinical improvement and reversal of the PRP-associated molecular signature with a 50% improvement in skin lesions after 2 to 3 weeks. This transcriptional signature was consistent with in vitro stimulation of keratinocytes with IL-1β. With the central role of IL-1β underscoring its potential as a therapeutic target, our findings propose a redefinition of PRP as an autoinflammatory keratinization disorder. Further clinical trials are needed to validate the efficacy of IL-1β antagonists in PRP.
Collapse
Affiliation(s)
- Eloi Schmauch
- Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
- Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
- A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
| | - Yannik Severin
- Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, 8049 Zurich, Switzerland
| | - Xianying Xing
- Departments of Internal Medicine and Dermatology, University of Michigan, Ann Arbor, MI 48109, USA
| | - Aaron Mangold
- Department of Dermatology, Mayo Clinic Arizona, Scottsdale, AZ 85259, USA
| | - Curdin Conrad
- Department of Dermatology, CHUV University Hospital and University of Lausanne (UNIL), Lausanne, Switzerland
| | - Pål Johannsen
- Department of Dermatology, University of Zurich and University Hospital Zurich, Zurich, Switzerland
| | - J. Michelle Kahlenberg
- Departments of Internal Medicine and Dermatology, University of Michigan, Ann Arbor, MI 48109, USA
| | - Mark Mellett
- Department of Dermatology, University of Zurich and University Hospital Zurich, Zurich, Switzerland
| | - Alexander Navarini
- Department of Biomedicine and Dermatology Department, University Hospital of Basel, Basel, Switzerland
| | - Stefan Nobbe
- Department of Dermatology, University of Zurich and University Hospital Zurich, Zurich, Switzerland
- Department of Dermatology, Cantonal Hospital Frauenfeld, Frauenfeld, Switzerland
| | - Mrinal K. Sarkar
- Departments of Internal Medicine and Dermatology, University of Michigan, Ann Arbor, MI 48109, USA
| | - Abhigyan Satyam
- Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
| | - Lam C. Tsoi
- Departments of Internal Medicine and Dermatology, University of Michigan, Ann Arbor, MI 48109, USA
| | - Lars E. French
- Department of Dermatology and Allergology, Ludwig Maximilian University of Munich, Munich, Germany
- Dr. Philip Frost, Department of Dermatology and Cutaneous Surgery, University of Miami Miller School of Medicine, Miami, FL 33125, USA
| | - Jakob Nilsson
- Department of Immunology, University Hospital Zurich, Zurich, Switzerland
| | - Suvi Linna-Kuosmanen
- Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
- A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
| | - Minna U. Kaikkonen
- A.I. Virtanen Institute for Molecular Sciences, University of Eastern Finland, Kuopio, Finland
| | - Berend Snijder
- Institute of Molecular Systems Biology, Department of Biology, ETH Zurich, 8049 Zurich, Switzerland
| | - Manolis Kellis
- Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA
- Computer Science and Artificial Intelligence Laboratory, Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - Johann E. Gudjonsson
- Departments of Internal Medicine and Dermatology, University of Michigan, Ann Arbor, MI 48109, USA
- Taubman Medical Research Institute, University of Michigan, Ann Arbor, MI 48109, USA
| | - George C. Tsokos
- Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
| | - Emmanuel Contassot
- Department of Biomedicine and Dermatology Department, University Hospital of Basel, Basel, Switzerland
| | - Antonios G. A. Kolios
- Department of Dermatology, University of Zurich and University Hospital Zurich, Zurich, Switzerland
- Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA 02215, USA
- University of Zurich, Zurich, Switzerland
| |
Collapse
|
3
|
Montero-Menárguez J, Amat Samaranch V, Puig Sanz L, Ruiz-Villaverde R, Arias-Santiago S, Larrea García M, Ruiz Genao D, Ferrán M, Schneller-Pavelescu L, Romero Ferreiro C, Rivera Díaz R. Pityriasis Rubra Pilaris: A Multicentric Case Series of 65 Spanish Patients. ACTAS DERMO-SIFILIOGRAFICAS 2024:S0001-7310(24)00526-X. [PMID: 38964605 DOI: 10.1016/j.ad.2024.07.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2023] [Revised: 12/13/2023] [Accepted: 02/06/2024] [Indexed: 07/06/2024] Open
Abstract
INTRODUCTION PRP is a rare entity of unknown etiopathogenesis. Lack of management guidelines makes it a challenge for clinicians. OBJECTIVE To add our experience to increase evidence about PRP. METHODS We performed a retrospective, descriptive and multicentric study of 65 patients with PRP, being the largest European case series of patients with PRP. RESULTS PRP was more frequent in male patients with an average age of 51 years, but erythrodermic forms presented in older patients (average age 61 years). Six (75%) paediatric patients and ten (60%) non-erythrodermic adults controlled their disease with topical corticosteroids. On the contrary, 26 (68%) erythrodermic patients required biologic therapy as last and effective therapy line requiring an average of 6.5 months to achieve complete response. CONCLUSION Our study showed a statistical difference in terms of outcome and response to treatment between children or patients with limited disease and patients who develop erythroderma.
Collapse
Affiliation(s)
- J Montero-Menárguez
- Dermatology Department of the Hospital Universitario 12 de Octubre, Madrid, España.
| | - V Amat Samaranch
- Dermatology Department of Hospital de la Santa Creu i Sant Pau de Barcelona, España
| | - L Puig Sanz
- Dermatology Department of Hospital de la Santa Creu i Sant Pau de Barcelona, España
| | - R Ruiz-Villaverde
- Dermatology Department of Hospital Universitario San Cecilio de Granada, España
| | - S Arias-Santiago
- Dermatology Department of Hospital Virgen de las Nieves de Granada, School of Medicine, Granada University, Instituto de Investigación Biosanitaria IBS, Granada, España
| | - M Larrea García
- Dermatology Department of Hospital Universitario de Navarra, España
| | - D Ruiz Genao
- Dermatology Department of Fundación Hospital Alcorcón, España
| | - M Ferrán
- Dermatology Department of Hospital del Mar de Barcelona, España
| | | | - C Romero Ferreiro
- Unidad de Soporte Científico, Instituto de Investigación Sanitaria, Hospital Universitario 12 de Octubre, España; Facultad de Ciencias de la Salud, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Madrid, España
| | - R Rivera Díaz
- Dermatology Department of the Hospital Universitario 12 de Octubre, Madrid, España
| |
Collapse
|
4
|
Vieira Granja B, Amoedo P, Gomes NP, Costa C, Azevedo F, Magina S. Pityriasis rubra pilaris after COVID-19 vaccination: successful treatment with ustekinumab. An Bras Dermatol 2024; 99:642-644. [PMID: 38653608 PMCID: PMC11221136 DOI: 10.1016/j.abd.2023.07.009] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/09/2023] [Revised: 07/09/2023] [Accepted: 07/10/2023] [Indexed: 04/25/2024] Open
Affiliation(s)
- Bárbara Vieira Granja
- Department of Dermatology and Venereology, Centro Hospitalar Universitário de São João, EPE, Porto, Portugal.
| | - Patrícia Amoedo
- Department of Dermatology and Venereology, Centro Hospitalar Universitário de São João, EPE, Porto, Portugal
| | - Nuno Preto Gomes
- Department of Dermatology and Venereology, Centro Hospitalar Universitário de São João, EPE, Porto, Portugal
| | - Catarina Costa
- Department of Pathology, Centro Hospitalar Universitário de São João, EPE, Porto, Portugal
| | - Filomena Azevedo
- Department of Dermatology and Venereology, Centro Hospitalar Universitário de São João, EPE, Porto, Portugal
| | - Sofia Magina
- Department of Dermatology and Venereology, Centro Hospitalar Universitário de São João, EPE, Porto, Portugal; Department of Biomedicine, Faculty of Medicine, Universidade do Porto, Porto, Portugal
| |
Collapse
|
5
|
Abstract
Patients living with HIV may experience a variety of inflammatory dermatoses, ranging from exacerbations of underlying conditions to those triggered by HIV infection itself. This article presents a current literature review on the etiology, diagnosis and management of atopic dermatitis, psoriasis, pityriasis rubra pilaris, lichen planus, seborrheic dermatitis, eosinophilic folliculitis, pruritic papular eruption and pruritus, in patients living with HIV.
Collapse
Affiliation(s)
- Robert Bobotsis
- Division of Dermatology, Department of Medicine, Faculty of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada
| | - Shakira Brathwaite
- Division of Dermatology, Department of Medicine, Faculty of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada
| | - Panteha Eshtiaghi
- Division of Dermatology, Department of Medicine, Faculty of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada
| | - Fabian Rodriguez-Bolanos
- Division of Dermatology, Department of Medicine, Faculty of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada
| | - Philip Doiron
- Division of Dermatology, Department of Medicine, Faculty of Medicine, University of Toronto School of Medicine, Toronto, Ontario, Canada.
| |
Collapse
|
6
|
Zhou T, Al Muqrin A, Abu-Hilal M. Updates on Pityriasis Rubra Pilaris: A Scoping Review. J Cutan Med Surg 2024; 28:158-166. [PMID: 38174859 PMCID: PMC11015718 DOI: 10.1177/12034754231223159] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/05/2024]
Abstract
Pityriasis rubra pilaris (PRP) is a rare, inflammatory papulosquamous skin disease with unknown exact etiology. Historically, PRP has been challenging to diagnose, especially during the acute phase, and to treat, due to its unclear pathogenesis. To better inform clinical practice, a literature review was conducted employing a broad search strategy to capture PRP-related published studies between January 1, 2012 to October 31, 2022. Two hundred twenty-one studies were identified, which were categorized into 9 themes: (1) potential causes and triggering factors, (2) comorbidities, (3) diagnostic difficulties, (4) genetics, (5) clinical manifestations and laboratory values, (6) treatment, (7) treatment-related adverse events, (8) quality of life, and (9) other. COVID-19 infection, COVID-19 vaccination, and malignancy were the most commonly reported potential triggering factors. Misdiagnosis is very common during the early acute stages. Pathogenesis and genetic studies have further implicated caspase recruitment domain family member 14 (CARD14) mutations in the development of familial PRP (Type V) and have underlined the overlap between psoriasis and PRP. To date, there are currently no specific and validated scoring systems or tools to assess the severity of PRP. While large, randomized trials are still lacking, biologic agents remain the most effective therapy.
Collapse
Affiliation(s)
- Ted Zhou
- Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
| | - Abdullah Al Muqrin
- Division of Dermatology, Department of Medicine, McMaster University, Hamilton, ON, Canada
| | - Mohannad Abu-Hilal
- Michael G. DeGroote School of Medicine, McMaster University, Hamilton, ON, Canada
- Division of Dermatology, Department of Medicine, McMaster University, Hamilton, ON, Canada
| |
Collapse
|
7
|
Montero-Menárguez J, Amat Samaranch V, Puig Sanz L, Ruiz-Villaverde R, Arias-Santiago S, Larrea García M, Ruiz Genao D, Ferrán M, Schneller-Pavelescu L, Romero Ferreiro C, Rivera Díaz R. Pityriasis Rubra Pilaris: A Multicentric Case Series of 65 Spanish Patients. ACTAS DERMO-SIFILIOGRAFICAS 2024:S0001-7310(24)00161-3. [PMID: 38401879 DOI: 10.1016/j.ad.2024.02.019] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/24/2023] [Revised: 12/13/2023] [Accepted: 02/06/2024] [Indexed: 02/26/2024] Open
Abstract
INTRODUCTION PRP is a rare entity of unknown etiopathogenesis. Lack of management guidelines makes it a challenge for clinicians. OBJECTIVE To add our experience to increase evidence about PRP. METHODS We performed a retrospective, descriptive and multicentric study of 65 patients with PRP, being the largest European case series of patients with PRP. RESULTS PRP was more frequent in male patients with an average age of 51 years, but erythrodermic forms presented in older patients (average age 61 years). Six (75%) paediatric patients and ten (60%) non-erythrodermic adults controlled their disease with topical corticosteroids. On the contrary, 26 (68%) erythrodermic patients required biologic therapy as last and effective therapy line requiring an average of 6.5 months to achieve complete response. CONCLUSION Our study showed a statistical difference in terms of outcome and response to treatment between children or patients with limited disease and patients who develop erythroderma.
Collapse
Affiliation(s)
- J Montero-Menárguez
- Dermatology Department of the Hospital Universitario 12 de Octubre, Madrid, Spain.
| | - V Amat Samaranch
- Dermatology Department of Hospital de la Santa Creu i Sant Pau de Barcelona, Spain
| | - L Puig Sanz
- Dermatology Department of Hospital de la Santa Creu i Sant Pau de Barcelona, Spain
| | - R Ruiz-Villaverde
- Dermatology Department of Hospital Universitario San Cecilio de Granada, Spain
| | - S Arias-Santiago
- Dermatology Department of Hospital Virgen de las Nieves de Granada, School of Medicine, Granada University, Instituto de Investigación Biosanitaria IBS, Granada, Spain
| | - M Larrea García
- Dermatology Department of Hospital Universitario de Navarra, Spain
| | - D Ruiz Genao
- Dermatology Department of Fundación Hospital Alcorcón, Spain
| | - M Ferrán
- Dermatology Department of Hospital del Mar de Barcelona, Spain
| | | | - C Romero Ferreiro
- Unidad de Soporte Científico, Instituto de Investigación Sanitaria, Hospital Universitario 12 de Octubre, Spain; Facultad de Ciencias de la Salud, Universidad Francisco de Vitoria, Pozuelo de Alarcón, Madrid, Spain
| | - R Rivera Díaz
- Dermatology Department of the Hospital Universitario 12 de Octubre, Madrid, Spain
| |
Collapse
|
8
|
Fydanaki O, Rezq H, Sepetis AE, Joganathan V. Resolution of Pityriasis rubra pilaris induced ectropion with oral dexamethasone. A case report. Orbit 2024:1-3. [PMID: 38319642 DOI: 10.1080/01676830.2024.2311657] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/30/2023] [Accepted: 01/24/2024] [Indexed: 02/07/2024]
Abstract
An 82-year-old male presented with generalised Pityriasis rubra pilaris (PRP) managed initially by dermatology team. The patient did not respond to first- and second-line treatment, including oral acitretin, steroid creams, and methotrexate, and developed bilateral cicatricial ectropion, for which he was referred to oculoplastic team for surgical management. A head injury resulting in subacute subdural haematoma, managed with a week course of low dose oral dexamethasone, resulted in the improvement of his skin condition and complete resolution of the cicatricial ectropion within a few weeks. Thus, systemic treatment of PRP with oral dexamethasone may be considered sooner in the treatment of cicatricial ectropion in similar cases.
Collapse
Affiliation(s)
- Ourania Fydanaki
- Ophthalmology Department, University Hospital Southampton NHS Foundation Trust, Southampton, UK
| | - Haytham Rezq
- Ophthalmology Department, University Hospital Southampton NHS Foundation Trust, Southampton, UK
| | - Anastasios E Sepetis
- Ophthalmology Department, University Hospital Southampton NHS Foundation Trust, Southampton, UK
| | - Varajini Joganathan
- Ophthalmology Department, University Hospital Southampton NHS Foundation Trust, Southampton, UK
| |
Collapse
|
9
|
Blicharz L, Czuwara J, Rudnicka L, Torrelo A. Autoinflammatory Keratinization Diseases-The Concept, Pathophysiology, and Clinical Implications. Clin Rev Allergy Immunol 2023; 65:377-402. [PMID: 38103162 PMCID: PMC10847199 DOI: 10.1007/s12016-023-08971-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 09/24/2023] [Indexed: 12/17/2023]
Abstract
Recent advances in medical genetics elucidated the background of diseases characterized by superficial dermal and epidermal inflammation with resultant aberrant keratosis. This led to introducing the term autoinflammatory keratinization diseases encompassing entities in which monogenic mutations cause spontaneous activation of the innate immunity and subsequent disruption of the keratinization process. Originally, autoinflammatory keratinization diseases were attributed to pathogenic variants of CARD14 (generalized pustular psoriasis with concomitant psoriasis vulgaris, palmoplantar pustulosis, type V pityriasis rubra pilaris), IL36RN (generalized pustular psoriasis without concomitant psoriasis vulgaris, impetigo herpetiformis, acrodermatitis continua of Hallopeau), NLRP1 (familial forms of keratosis lichenoides chronica), and genes of the mevalonate pathway, i.e., MVK, PMVK, MVD, and FDPS (porokeratosis). Since then, endotypes underlying novel entities matching the concept of autoinflammatory keratinization diseases have been discovered (mutations of JAK1, POMP, and EGFR). This review describes the concept and pathophysiology of autoinflammatory keratinization diseases and outlines the characteristic clinical features of the associated entities. Furthermore, a novel term for NLRP1-associated autoinflammatory disease with epithelial dyskeratosis (NADED) describing the spectrum of autoinflammatory keratinization diseases secondary to NLRP1 mutations is proposed.
Collapse
Affiliation(s)
- Leszek Blicharz
- Department of Dermatology, Medical University of Warsaw, 02-008, Warsaw, Poland
| | - Joanna Czuwara
- Department of Dermatology, Medical University of Warsaw, 02-008, Warsaw, Poland.
| | - Lidia Rudnicka
- Department of Dermatology, Medical University of Warsaw, 02-008, Warsaw, Poland
| | - Antonio Torrelo
- Department of Dermatology, University Children's Hospital Niño Jesús, 28009, Madrid, Spain.
| |
Collapse
|
10
|
Sood S, Akuffo-Addo E, Yeung J, Mufti A. Biologic treatment options for pityriasis rubra pilaris: An evidence-based systematic review. J Am Acad Dermatol 2023; 89:1306-1308. [PMID: 37640244 DOI: 10.1016/j.jaad.2023.08.057] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2023] [Revised: 08/10/2023] [Accepted: 08/12/2023] [Indexed: 08/31/2023]
Affiliation(s)
- Siddhartha Sood
- Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
| | - Edgar Akuffo-Addo
- Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada
| | - Jensen Yeung
- Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Department of Dermatology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada; Department of Dermatology, Women's College Hospital, Toronto, Ontario, Canada; Probity Medical Research, Waterloo, Ontario, Canada
| | - Asfandyar Mufti
- Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Ontario, Canada; Department of Dermatology, Sunnybrook Health Sciences Centre, Toronto, Ontario, Canada.
| |
Collapse
|
11
|
Potestio L, Martora F, Villani A, Megna M, Ruggiero A. Comment on: 'Clinical characteristics of patients with pityriasis rubra pilaris following SARS-CoV-2 vaccination' by Gambichler. J Eur Acad Dermatol Venereol 2023; 37:e1196-e1197. [PMID: 37326210 DOI: 10.1111/jdv.19264] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/14/2023] [Accepted: 06/12/2023] [Indexed: 06/17/2023]
Affiliation(s)
- Luca Potestio
- Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - Fabrizio Martora
- Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - Alessia Villani
- Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - Matteo Megna
- Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - Angelo Ruggiero
- Section of Dermatology - Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| |
Collapse
|
12
|
Kołt-Kamińska M, Osińska A, Kaznowska E, Reich A. Successful Treatment of Pityriasis Rubra Pilaris with Risankizumab in Children. Dermatol Ther (Heidelb) 2023; 13:2431-2441. [PMID: 37704911 PMCID: PMC10539248 DOI: 10.1007/s13555-023-01005-y] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/04/2023] [Accepted: 08/03/2023] [Indexed: 09/15/2023] Open
Abstract
Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disease that affects men and women of all ages, including children. PRP is characterized by follicular and palmoplantar hyperkeratosis and salmon-colored scaling plaques. The exact pathogenesis of PRP is still unknown; most PRP cases are acquired, but some cases may show a familial occurrence, often associated with a mutation in the CARD14 gene. Due to the rarity of PRP, treatment recommendations are based mainly on case reports, small case series and expert opinions and still represent a major therapeutic challenge, especially in children. A growing number of reports on treatment with biologicals, particularly anti-TNFα, has been published. However, an involvement of the IL-23/Th17 axis in both psoriasis and PRP pathogenesis may suggest that this pathway may be a potential therapeutic target. Here, we present three pediatric patients with PRP successfully treated with risankizumab. All patients exhibited a severe course of PRP and lack of response to conventional therapy, including acitretin, cyclosporine and phototherapy. A single dose of 75 mg risankizumab resulted in almost complete clearance of skin lesions in case 1 and 2 at week 4. In patient 3, clear skin was achieved after the second administration of risankizumab (150 mg). All patients continue the treatment with risankizumab, and no adverse effects have been reported up to the present time. Our study demonstrates that risankizumab, an IL-23 blocker, shows good efficacy and safety among pediatric patients with PRP.
Collapse
Affiliation(s)
- Marta Kołt-Kamińska
- Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, Szopena 2, 35-055, Rzeszów, Poland
| | | | - Ewa Kaznowska
- Department of Pathomorphology, Institute of Medical Sciences, Medical College of Rzeszow University, Rzeszów, Poland
| | - Adam Reich
- Department of Dermatology, Institute of Medical Sciences, Medical College of Rzeszow University, Szopena 2, 35-055, Rzeszów, Poland.
| |
Collapse
|
13
|
Ying Y, Yu-Hua L, Xiao-Yan W, Su-Chun H. A case of pityriasis rubra pilaris treated with tofacitinib after failure with acitretin and ixekizumab. Australas J Dermatol 2023; 64:445-447. [PMID: 37200390 DOI: 10.1111/ajd.14076] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/02/2023] [Revised: 04/12/2023] [Accepted: 04/28/2023] [Indexed: 05/20/2023]
Affiliation(s)
- Yang Ying
- Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China
| | - Liu Yu-Hua
- Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China
| | - Wu Xiao-Yan
- Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China
| | - Hou Su-Chun
- Department of Dermatology, The University of Hong Kong-Shenzhen Hospital, Shenzhen, China
| |
Collapse
|
14
|
Chakraborty A. Disease severity scores in dermatology: An update of the various indices. Indian J Dermatol Venereol Leprol 2023; 0:1-15. [PMID: 37436018 DOI: 10.25259/ijdvl_592_2021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/14/2021] [Accepted: 06/15/2022] [Indexed: 07/13/2023]
Affiliation(s)
- Atreyo Chakraborty
- Department of Dermatology Venereology & Leprosy, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India
| |
Collapse
|
15
|
Abduljawad M, Alsharif TH, Gronfula AG, Magadmi TK, Khayat LI, Fageeh SM, Almuallim AA, Mohammad MA, Albadri A. The Effectiveness of Anti-Interleukin-17A Treatment for Pityriasis Rubra Pilaris: A Systematic Review. Cureus 2023; 15:e41125. [PMID: 37519579 PMCID: PMC10382908 DOI: 10.7759/cureus.41125] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 06/29/2023] [Indexed: 08/01/2023] Open
Abstract
Anti-interleukin-17A (anti-IL-17A) therapy has been increasingly employed as a treatment option for pityriasis rubra pilaris (PRP). In this study, we reviewed all available studies on this topic in the literature to evaluate the efficacy and safety of anti-IL-17A. Our main objective was to assess the current evidence on the efficacy and safety of anti-IL-17A therapy in the management of PRP. We searched for relevant articles on PubMed, MEDLINE, Ovid, Embase, and the Web of Science electronic databases from inception until 2022. Our inclusion criteria were as follows: randomized controlled trials (RCTs), quasi-randomized trials, or prospective observational studies that include PRP patients treated with biological treatments; studies that report clinical outcomes; and studies that compare the treatment modalities, including anti-IL-17, in the English language. A total of 19 articles involving 77 cases were reviewed after applying the inclusion criteria and removing duplicates. We found that type 1 PRP was the most common condition irrespective of gender, and the trunk was the most affected area. The study showed that IL-17 inhibitors had a significant impact on the patients. However, higher-level studies are required to further evaluate the therapeutic and safety effects of the treatment.
Collapse
Affiliation(s)
| | | | - Amin G Gronfula
- Orthopaedic Surgery, Royal College of Surgeons in Ireland, Dublin, IRL
| | - Talah K Magadmi
- Medicine and Surgery, King Abdulaziz University, Jeddah, SAU
| | | | - Sarah M Fageeh
- Medicine, Faculty of Medicine, Umm Al-Qura University, Makkah, SAU
| | | | | | | |
Collapse
|
16
|
Saad M, Spurr A, Lipson J. Pityriasis rubra pilaris partially responsive to treatment with upadacitinib: A case report. SAGE Open Med Case Rep 2023; 11:2050313X231160927. [PMID: 37009550 PMCID: PMC10064474 DOI: 10.1177/2050313x231160927] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/31/2023] Open
Abstract
Pityriasis rubra pilaris is a rare inflammatory dermatosis characterized by orange-red confluent plaques, hyperkeratotic follicular papules, palmoplantar keratoderma, and, in some cases, erythroderma. The etiology of pityriasis rubra pilaris is unclear. This condition is often treated with oral retinoids and topical corticosteroids, and more recently, biological agents have become the mainstay of treatment. However, there is a paucity of high-quality evidence on the safety and effectiveness of these agents, and the disease often remains refractory to therapy. Herein, we present a case of pityriasis rubra pilaris with a favorable response to treatment with upadacitinib, a Janus kinase inhibitor, which has not been previously reported in the literature for the management of this condition.
Collapse
Affiliation(s)
- Mysa Saad
- Faculty of Medicine, University of Ottawa, Ottawa, ON, Canada
| | - Alison Spurr
- Division of Dermatology, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada
| | - Jennifer Lipson
- Division of Dermatology, The Ottawa Hospital, University of Ottawa, Ottawa, ON, Canada
- Jennifer Lipson, Division of Dermatology, The Ottawa Hospital, University of Ottawa, 737 Parkdale Avenue, Ottawa, ON K1Y 4M9, Canada.
| |
Collapse
|
17
|
Balak DMW, Rissmann R. Anti-interleukin-17A for pityriasis rubra pilaris: catching the psoriasis biologic wave. Br J Dermatol 2022; 187:633-634. [PMID: 35996840 PMCID: PMC10015986 DOI: 10.1111/bjd.21813] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/23/2022] [Accepted: 07/26/2022] [Indexed: 11/29/2022]
Abstract
Linked Article: Boudreaux et al. Br J Dermatol 2022; 187:650–658.
Collapse
Affiliation(s)
- Deepak M W Balak
- Department of Dermatology, Leiden University Medical Center, Leiden, the Netherlands
| | - Robert Rissmann
- Centre for Human Drug Research, Leiden, the Netherlands.,Leiden Academic Centre for Drug Research, Leiden University, Leiden, the Netherlands
| |
Collapse
|
18
|
Muacevic A, Adler JR. Physiotherapy Management of an Adolescent With Pityriasis Rubra Pilaris Along With Rickets. Cureus 2022; 14:e30518. [PMID: 36415347 PMCID: PMC9674203 DOI: 10.7759/cureus.30518] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2022] [Accepted: 10/20/2022] [Indexed: 01/25/2023] Open
Abstract
Rickets is an ossification and mineralization disorder of the growth plate before skeletal maturity that is peculiar to children and adolescents. Most children are affected by this deficient disorder throughout their skeletal growth stage, characterized by deformed and soft bones, due to a failure to assimilate and utilize calcium and phosphorus properly. It is most frequent in children aged four months to three years in developing countries. In the Indian subcontinent, it continues to be a major health problem. The majority of rickets symptoms include bone pain, deformity of the bones, and impaired growth velocity. In addition to damaging the skeletal system, it also affects other systems, which results in substantial morbidity. The term "rachitic pneumopathy" has long been used to describe respiratory issues caused by rickets. Pityriasis rubra pilaris (PRP) is an inflammatory rare skin disease that affects children as well as adults of all ages. They can develop PRP's clinical characteristics and individual prognoses are quite varied. Rickets occurring in association with skin diseases is rare. Here, we report an instance of a 15-year-old boy who gave a history of pain and swelling in the knees for the past three months. He couldn't bear weight and had walking difficulty as well. Along with this, he also complained of itchy lesions for nine years. Initially, the lesions were on the right arm, which progressed to the left arm, chest, back and abdomen. Later, they were seen on the lower limbs. After appropriate diagnostic work, he was diagnosed with rickets with pityriasis rubra pilaris. The patient received both medical and physical therapy treatment. The physical therapy rehabilitation program used in this case study significantly improved the patient's functional independence by reducing pain and improving joint mobility, muscle strength, endurance, and gait. After six weeks of rehabilitation, there was an improvement in the ranges of the joint, strength of muscle, gait, and functional independence significantly using physical therapy techniques. This case study shows the value of comprehensive physical therapy in a case of pityriasis rubra pilaris with rickets in a 15-year-old boy.
Collapse
|
19
|
Shakshouk H, Erickson LA, Johnson EF, Lehman JS. Updates and Proposed Diagnostic Approach to Psoriasiform Dermatoses. Adv Anat Pathol 2022; 29:263-274. [PMID: 35180737 DOI: 10.1097/pap.0000000000000333] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
Abstract
Psoriasiform dermatoses represent a wide array of skin diseases commonly encountered by clinicians and pathologists. While they may present a diagnostic challenge, thorough observation coupled with proper interpretation of subtle additional clinical or histopathologic features provide clues to the correct diagnosis. In this review, we provide updates on emerging entities and develop a systemic approach to establish the pathologic diagnosis, with emphasis on the importance of clinicopathologic correlation.
Collapse
Affiliation(s)
- Hadir Shakshouk
- Departments of Dermatology
- Department of Dermatology, Alexandria University, Alexandria, Egypt
| | - Lori A Erickson
- Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
| | - Emma F Johnson
- Departments of Dermatology
- Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
| | - Julia S Lehman
- Departments of Dermatology
- Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN
| |
Collapse
|
20
|
Iznardo H, Puig L. Beyond plaque psoriasis - pathogenesis and treatment of other psoriasis phenotypes. Curr Opin Rheumatol 2022; 34:225-234. [PMID: 35699337 DOI: 10.1097/bor.0000000000000882] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/15/2022]
Abstract
PURPOSE OF REVIEW Psoriasis vulgaris is the commonest presentation of psoriatic disease, but morphologic variants such as pustular psoriasis (PP) and a closely related disease, pityriasis rubra pilaris (PRP), have been known for a long time, have been associated with rheumatologic manifestations indistinguishable from psoriatic arthritis (PsA) that may go unrecognized, and often represent a therapeutic conundrum. There is recent evidence that underlying genetic and pathogenetic differences may provide the basis for newer therapeutic approaches. RECENT FINDINGS This narrative review highlights the clinical, genetic and pathogenetic characteristics of PP and PRP, their association with PsA and recent developments in their treatment, especially with biologic agents targeting IL-36 and other cytokines of pathogenic relevance. SUMMARY The clinical manifestations of PP and PRP are less well known to rheumatologists than those of psoriasis, and recent advances in our insight on their pathogenesis may eventually overcome the therapeutic difficulties faced by dermatologists and rheumatologists in the management of these diseases and their rheumatologic manifestations.
Collapse
Affiliation(s)
- Helena Iznardo
- Department of Dermatology, Hospital de la Santa Creu i Sant Pau, Universitat Autònoma, Barcelona, Spain
| | | |
Collapse
|
21
|
Katharina M, Sylvia S, Matthias B, Ulrich M, Martin L. Successful treatment of a child's pityriasis rubra pilaris (PRP) with ustekinumab and acitretin. Pediatr Dermatol 2022; 39:659-661. [PMID: 35859269 PMCID: PMC9541132 DOI: 10.1111/pde.14994] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 09/07/2021] [Revised: 01/25/2022] [Accepted: 03/19/2022] [Indexed: 11/26/2022]
Abstract
Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disease that occurs with phenotypic variability in adults of all ages as well as in children. Data on the treatment of PRP is limited. Here, we report a 5-year-old girl with widespread skin involvement and prominent palmoplantar hyperkeratosis who was initially treated for psoriasis. After reevaluation, a diagnosis of PRP was made, and the patient had an excellent therapeutic response to ustekinumab and acitretin.
Collapse
Affiliation(s)
- Medek Katharina
- Department of DermatologyUniversity Hospital of the Paracelsus Medical University SalzburgSalzburgAustria
| | - Selhofer Sylvia
- Department of DermatologyUniversity Hospital of the Paracelsus Medical University SalzburgSalzburgAustria
| | - Buchner Matthias
- Department of PediatricsUniversity Hospital of the Paracelsus Medical University SalzburgSalzburgAustria
| | - Mrowietz Ulrich
- Psoriasis‐Center at the Department of DermatologyUniversity Medical Center Schleswig‐HolsteinKielGermany
| | - Laimer Martin
- Department of DermatologyUniversity Hospital of the Paracelsus Medical University SalzburgSalzburgAustria
| |
Collapse
|
22
|
Ajebo EM, Howard JD, Anand D, Davis LS. Pityriasis Rubra Pilaris Potentially Triggered by mRNA-1273 COVID Vaccine. JAAD Case Rep 2022; 23:114-116. [PMID: 35465138 PMCID: PMC9013576 DOI: 10.1016/j.jdcr.2022.03.013] [Citation(s) in RCA: 6] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
23
|
Arora A, Mohta A, Ghiya BC, Jangir VK. Acute postinfectious type III pityriasis rubra pilaris as a cutaneous manifestation in COVID-19: decoding a possible trigger!! J Cosmet Dermatol 2022; 21:3206-3207. [PMID: 35332643 PMCID: PMC9115116 DOI: 10.1111/jocd.14933] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2022] [Accepted: 03/21/2022] [Indexed: 11/27/2022]
Affiliation(s)
- Aakanksha Arora
- Department of Dermatology, Venereology and Leprology, Sardar Patel Medical College, Bikaner, Rajasthan, India
| | - Alpana Mohta
- Department of Dermatology, Venereology and Leprology, Sardar Patel Medical College, Bikaner, Rajasthan, India
| | - Bhikam Chand Ghiya
- Department of Dermatology, Venereology and Leprology, Sardar Patel Medical College, Bikaner, Rajasthan, India
| | - Vishnu Kumar Jangir
- Department of Dermatology, Venereology and Leprology, Sardar Patel Medical College, Bikaner, Rajasthan, India
| |
Collapse
|
24
|
Altered replication stress response due to CARD14 mutations promotes recombination-induced revertant mosaicism. Am J Hum Genet 2021; 108:1026-1039. [PMID: 34004138 DOI: 10.1016/j.ajhg.2021.04.021] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/14/2020] [Accepted: 04/22/2021] [Indexed: 01/07/2023] Open
Abstract
Revertant mosaicism, or "natural gene therapy," refers to the spontaneous in vivo reversion of an inherited mutation in a somatic cell. Only approximately 50 human genetic disorders exhibit revertant mosaicism, implicating a distinctive role played by mutant proteins in somatic correction of a pathogenic germline mutation. However, the process by which mutant proteins induce somatic genetic reversion in these diseases remains unknown. Here we show that heterozygous pathogenic CARD14 mutations causing autoinflammatory skin diseases, including psoriasis and pityriasis rubra pilaris, are repaired mainly via homologous recombination. Rather than altering the DNA damage response to exogenous stimuli, such as X-irradiation or etoposide treatment, mutant CARD14 increased DNA double-strand breaks under conditions of replication stress. Furthermore, mutant CARD14 suppressed new origin firings without promoting crossover events in the replication stress state. Together, these results suggest that mutant CARD14 alters the replication stress response and preferentially drives break-induced replication (BIR), which is generally suppressed in eukaryotes. Our results highlight the involvement of BIR in reversion events, thus revealing a previously undescribed role of BIR that could potentially be exploited to develop therapeutics for currently intractable genetic diseases.
Collapse
|
25
|
Kadylak D, Barańska-Rybak W. Acute postinfectious pityriasis rubra pilaris as a cutaneous manifestation in COVID-19: a case report and its dermoscopic features. J Eur Acad Dermatol Venereol 2021; 35:e622-e624. [PMID: 34058019 PMCID: PMC8242759 DOI: 10.1111/jdv.17424] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/10/2021] [Accepted: 04/12/2021] [Indexed: 11/29/2022]
Affiliation(s)
- D Kadylak
- Department of Dermatology, Venereology and Allergology, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
| | - W Barańska-Rybak
- Department of Dermatology, Venereology and Allergology, Faculty of Medicine, Medical University of Gdańsk, Gdańsk, Poland
| |
Collapse
|
26
|
Kaczmarczyk R, King F, Biedermann T, Zink A. What's driving dermatology? Contribution title analysis of the largest German Dermatology Congress 2019. Digit Health 2021; 7:20552076211012138. [PMID: 33996141 PMCID: PMC8076776 DOI: 10.1177/20552076211012138] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/07/2020] [Accepted: 03/27/2021] [Indexed: 12/02/2022] Open
Abstract
Background Every two years, German-speaking dermatologic specialist groups gather in Berlin to share the latest developments at Germanýs largest dermatologic conference, the Annual Meeting of the Germany Society of Dermatology (DDG). Because this conference has a lasting effect on dermatologic practice and research, understanding what is moving the specialist groups means understanding what is driving dermatology in Germany. Methods We used word network analysis to compile and visualize the information embedded in the contribution titles to the DDG Annual Meeting in 2019. We extracted words, contributing cities and inter-connections. The data was standardized, visualized using network graphs and analyzed using common network analysis parameters. Results A total of 5509 words were extracted from 1150 contribution titles. The most frequently used words were “therapy”, “patients”, and “psoriasis”. The highest number of contributions came from Hamburg, Berlin and Munich. High diversity in research topics was found, as well as a well-connected research network. Conclusions Focus of the well-connected German-speaking dermatology community meeting 2019 was patient and therapy centered and lies especially on the diseases psoriasis and melanoma. Network graph analysis can provide helpful insights and help planning future congresses. It can facilitate the choice which contributors to include as imbalances become apparent. Moreover, it can help distributing the topics more evenly across the whole dermatologic spectrum.
Collapse
Affiliation(s)
- Robert Kaczmarczyk
- Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany
| | - Felix King
- Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany
| | - Tilo Biedermann
- Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany
| | - Alexander Zink
- Department of Dermatology and Allergy, School of Medicine, Technical University of Munich, Munich, Germany
| |
Collapse
|
27
|
Aguilar-Gamboa FR, Cubas-Alarcon D, Villegas-Chiroque M, Failoc-Rojas VE. Pityriasis rubra pilaris post-infection due COVID-19: case report. Colomb Med (Cali) 2021; 52:e7014577. [PMID: 33911322 PMCID: PMC8054706 DOI: 10.25100/cm.v52i1.4577] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/07/2023] Open
Abstract
Case description: 32-month-old boy, IgG positive for SARS-CoV-2, presented to the emergency department with dermatologic lesions. Clinical findings: Four days before admission, he presented skin eruptions with redness and pruritus on hands and feet. Generalized papular erythema was evidenced, upper extremities with diffuse erythematosquamous plaques, palmoplantar keratoderma, so he was evaluated by a dermatologist who diagnosed pityriasis rubra pilaris. Treatment and outcome: rehydrating cream, cetirizine 0.5 mg/kg/day every two days, and prednisolone 2 mg/kg/day in the morning. He was discharged after 14 days, the patient presented clinical improvement, but the erythematous lesion persisted on the trunk and extremities. In the evaluation, after three months, the patient did not show the described lesions, evidencing an improvement and clinical resolution of the dermatological problems. Clinical relevance: We report a patient with pityriasis rubra piloris associated with a post-infection by SARS-CoV-2 that had not been described before.
Collapse
Affiliation(s)
- Franklin R Aguilar-Gamboa
- Hospital Regional Lambayeque, Laboratorio de inmunología y virología, Dirección de Investigación. Chiclayo, Perú. Hospital Regional Lambayeque Laboratorio de inmunología y virología Dirección de Investigación Chiclayo Perú
| | - Dennis Cubas-Alarcon
- Hospital Regional Docente Belén de Lambayeque, Laboratorio de Microbiología, Servicio de Laboratorio Clínico, Belén de Lambayeque, Perú. Hospital Regional Docente Belén de Lambayeque Laboratorio de Microbiología Servicio de Laboratorio Clínico Belén de Lambayeque Perú
| | - Miguel Villegas-Chiroque
- Hospital Regional Lambayeque, Servicio de Infectología, Chiclayo, Perú. Hospital Regional Lambayeque Servicio de Infectología Chiclayo Perú
| | - Virgilio E Failoc-Rojas
- Universidad San Ignacio de Loyola, Lima, Perú. Universidad San Ignacio de Loyola Universidad San Ignacio de Loyola Lima Peru
| |
Collapse
|
28
|
Pityriasis rubra pilaris in skin of color. Int J Womens Dermatol 2021; 7:207-208. [PMID: 33937496 PMCID: PMC8072512 DOI: 10.1016/j.ijwd.2021.01.010] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/18/2020] [Revised: 12/14/2020] [Accepted: 01/06/2021] [Indexed: 12/27/2022] Open
|
29
|
Nielsen RM, Gram SB, Bygum A. Identification of a pathogenic CARD14 mutation in a 70-year-old woman with pityriasis rubra pilaris: when genetic diagnosis influences choice of treatment strategy. BMJ Case Rep 2021; 14:14/1/e235287. [PMID: 33431438 PMCID: PMC7802709 DOI: 10.1136/bcr-2020-235287] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/13/2023] Open
Abstract
Pityriasis rubra pilaris (PRP) is a rare dermatosis characterised by hyperkeratotic follicular papules, orange-red scaly plaques and palmoplantar keratoderma. The aetiology of the disease is in most cases unclear and treatment can be challenging. Familial cases of PRP may result from pathogenic variants in the caspase recruitment domain family member 14 (CARD14). We present a case of lifelong PRP in a 70-year-old woman, where genetic testing revealed a heterozygote missense variant c.412G>A, p.(Glu138Lys) in CARD14. Therapy with ustekinumab was initiated with remarkable effect, which improved the patient's quality of life significantly.
Collapse
Affiliation(s)
- Rikke Maria Nielsen
- Department of Dermatology and Allergy Center, Odense University Hospital, Odense, Denmark
| | - Stine Bjørn Gram
- Department of Clinical Genetics, Odense University Hospital, Odense, Denmark,Clinical Institute, University of Southern Denmark, Odense, Denmark
| | - Anette Bygum
- Department of Clinical Genetics, Odense University Hospital, Odense, Denmark,Clinical Institute, University of Southern Denmark, Odense, Denmark
| |
Collapse
|
30
|
Ezine E, Pedailles S, Dompmartin A, Morice C. Syndrome de fuite capillaire observé sous acitrétine : un cas et revue de la littérature. Ann Dermatol Venereol 2020; 147:535-541. [DOI: 10.1016/j.annder.2020.04.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/04/2019] [Revised: 03/26/2020] [Accepted: 04/14/2020] [Indexed: 10/23/2022]
|
31
|
Camela E, Miano C, Di Caterino P, Lo Presti M, De Fata Salvatores G, Fabbrocini G, Megna M. Erythrodermic pityriasis rubra pilaris treatment: Two case reports and literature review. Dermatol Ther 2020; 33:e14223. [PMID: 32820849 DOI: 10.1111/dth.14223] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/04/2020] [Revised: 08/07/2020] [Accepted: 08/17/2020] [Indexed: 01/16/2023]
Abstract
Pityriasis rubra pilaris (PRP) is a rare inflammatory dermatosis characterized by hyperkeratotic follicular papules and erythematous-desquamative plaques that tend to progressively evolve into erythroderma. Treatment is challenging given that international guidelines are not available and large-scale trials do not exist. Traditionally, many topical and systemic drugs had been used as consolidated agents; recently, biologicals are gaining increasing importance, promisingly dominating the therapeutic scenario ahead. Herein, we present a case series showing the "past" and the "future" therapeutic approaches to erythrodermic PRP, one case treated with acitretin and nb-UVB phototherapy combination, while the other with ustekinumab, performing also a throughout literature review.
Collapse
Affiliation(s)
- Elisa Camela
- Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - Chiara Miano
- Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - Paola Di Caterino
- Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - Maurizio Lo Presti
- Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - Gaia De Fata Salvatores
- Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - Gabriella Fabbrocini
- Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| | - Matteo Megna
- Section of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy
| |
Collapse
|
32
|
Lahouel M, Gammoudi R, Saidi W, Sriha B, Belajouza C, Denguezli M. Nilotinib-induced pityriasis rubra pilaris: First case report. Dermatol Ther 2020; 33:e14085. [PMID: 32720426 DOI: 10.1111/dth.14085] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/14/2020] [Revised: 07/20/2020] [Accepted: 07/24/2020] [Indexed: 11/26/2022]
Affiliation(s)
- Maha Lahouel
- Department of Dermatology, University of Sousse, Farhat Hached Hospital, Sousse, Tunisia
| | - Rima Gammoudi
- Department of Dermatology, University of Sousse, Farhat Hached Hospital, Sousse, Tunisia
| | - Wafa Saidi
- Department of Dermatology, University of Sousse, Farhat Hached Hospital, Sousse, Tunisia
| | - Badreddine Sriha
- Department of Pathology, University of Sousse, Farhat Hached Hospital, Sousse, Tunisia
| | - Colandane Belajouza
- Department of Dermatology, University of Sousse, Farhat Hached Hospital, Sousse, Tunisia
| | - Mohamed Denguezli
- Department of Dermatology, University of Sousse, Farhat Hached Hospital, Sousse, Tunisia
| |
Collapse
|
33
|
Chin LD, Parvinnejad N, Haber RM. Pityriasis in dermatology: an updated review. Int J Dermatol 2020; 60:141-158. [PMID: 32783190 DOI: 10.1111/ijd.15097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/16/2020] [Revised: 05/30/2020] [Accepted: 07/14/2020] [Indexed: 11/30/2022]
Abstract
Dermatology has a very distinctive lexicon. The term pityriasis refers to several dermatologic conditions which all feature scaling of the skin. According to the Merriam-Webster dictionary, the term pityriasis was first used in print in 1684. Although the diseases beginning with the name pityriasis are of diverse causation, they do represent important dermatologic diseases, with some common and others quite rare. It is important for dermatologists to be aware and updated on all pityriasis conditions in dermatology.
Collapse
Affiliation(s)
- Laura D Chin
- Cumming School of Medicine, University of Calgary, Calgary, AB, Canada
| | - Nikoo Parvinnejad
- Department of Pathology & Laboratory Medicine, University of Calgary, Calgary, AB, Canada
| | - Richard M Haber
- Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada
| |
Collapse
|
34
|
Mellett M. Regulation and dysregulation of CARD14 signalling and its physiological consequences in inflammatory skin disease. Cell Immunol 2020; 354:104147. [DOI: 10.1016/j.cellimm.2020.104147] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/06/2019] [Revised: 04/17/2020] [Accepted: 06/08/2020] [Indexed: 12/11/2022]
|
35
|
Gloor A, Rhyn M, Schlapbach C. Erythema gyratum repens‐like eruption after anti‐IL‐17 therapy of pityriasis rubra pilaris. J Eur Acad Dermatol Venereol 2020; 35:e38-e40. [DOI: 10.1111/jdv.16785] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- A.D. Gloor
- Department of Dermatology Inselspital Bern University Hospital Bern Switzerland
| | - M. Rhyn
- Department of Dermatology Inselspital Bern University Hospital Bern Switzerland
| | - C. Schlapbach
- Department of Dermatology Inselspital Bern University Hospital Bern Switzerland
| |
Collapse
|
36
|
De Felice C, Graceffa D, Morrone A, Bonifati C. Familial pityriasis rubra pilaris successfully treated with brodalumab. Int J Dermatol 2020; 59:885-887. [DOI: 10.1111/ijd.14857] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/13/2019] [Revised: 02/24/2020] [Accepted: 02/28/2020] [Indexed: 12/29/2022]
Affiliation(s)
- Catia De Felice
- Centre for the Study and Treatment of Psoriasis at the Department of Clinical Dermatology San Gallicano Dermatological Institute IRCCS Rome Italy
| | - Dario Graceffa
- Centre for the Study and Treatment of Psoriasis at the Department of Clinical Dermatology San Gallicano Dermatological Institute IRCCS Rome Italy
| | - Aldo Morrone
- Scientific Direction San Gallicano Dermatological Institute IRCCS Rome Italy
| | - Claudio Bonifati
- Centre for the Study and Treatment of Psoriasis at the Department of Clinical Dermatology San Gallicano Dermatological Institute IRCCS Rome Italy
| |
Collapse
|
37
|
Naidoo A, Sibbald C, Fleming PJ, Piguet V. Use of Biologics in Pityriasis Rubra Pilaris Refractory to First-Line Systemic Therapy: A Systematic Review [Formula: see text]. J Cutan Med Surg 2019; 24:73-78. [PMID: 31691587 DOI: 10.1177/1203475419887731] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/23/2022]
Abstract
Pityriasis rubra pilaris (PRP) is an uncommon, inflammatory, papulosquamous skin disease. Treatment of PRP is challenging as the disease is often refractory to conventional therapies, such as retinoids and methotrexate. There has been an increasing number of studies reporting the successful use of biologic therapy in patients with PRP; however, the data on the efficacy and safety are limited. Our objective was to evaluate the existing evidence for utilizing biologics, whether alone or in combination with established systemic therapies, in patients with treatment-resistant PRP. We systematically reviewed evidence within Medline and Pubmed databases between January 1, 2000, to March 31, 2019. Articles consisted of patients diagnosed with PRP who have failed to respond sufficiently to first-line systemic therapies, or who had comorbidities that precluded their use. In total, 363 unique articles were identified, 56 of which were considered relevant to the clinical question. Of the 56 articles highlighted, 35 met the inclusion criteria and were limited to case series and case studies. Therapy with biologics was found to be successful for both monotherapy (81.1% [27/33]) and when used in combination with existing systemic therapies (87.5% [14/16]). The existing evidence suggests that biologics may be regarded as a tool for PRP treatment alone or in combination therapy with existing treatments, although large-scale randomized clinical trials are necessary to better assess their efficacy and safety.
Collapse
Affiliation(s)
- Avee Naidoo
- 12366 210484 Division of Dermatology, Department of Medicine, University of Toronto, ON, Canada
| | - Cathryn Sibbald
- 6567 Section of Dermatology, Department of Pediatrics, The Children's Hospital of Philadelphia, Philadelphia, PA, USA
| | - Patrick J Fleming
- 12366 210484 Division of Dermatology, Department of Medicine, University of Toronto, ON, Canada
| | - Vincent Piguet
- 12366 210484 Division of Dermatology, Department of Medicine, University of Toronto, ON, Canada.,7938 Division of Dermatology, Department of Medicine, Women's College Hospital, Toronto, ON, Canada
| |
Collapse
|
38
|
Abstract
Pityriasis rubra pilaris (PRP) is a rare inflammatory skin disorder of unknown etiology, initially described in 1835. It is characterized by keratotic follicular papules, well-demarcated salmon-colored erythematous scaly plaques interspersed with distinct islands of uninvolved skin, and palmoplantar keratoderma. Is PRP a systemic disease? Skin is mainly affected in PRP. Despite its clinical heterogeneity, PRP could be associated with a variety of rheumatologic, infectious, neoplastic, and other extracutaneous manifestations. We accept the hypothesis of not only an association but also a causative relation between skin and systemic manifestations with possible common underlying pathomechanisms such as systemic immunologic processes and superantigen mimicry.
Collapse
|
39
|
Ralser‐Isselstein V, Balakirski G, Braun LM, Wenzel J, Altengarten J, Bieber T. Lokalisierte Pityriasis rubra pilaris in der Schwangerschaft: Eine sehr seltene Sonderform mit therapeutischer Herausforderung. J Dtsch Dermatol Ges 2019; 17 Suppl 2:28-30. [DOI: 10.1111/ddg.13787] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
Affiliation(s)
- Veronika Ralser‐Isselstein
- Klinik und Poliklinik für Dermatologie und AllergologieUniversitätsklinikum der Rheinischen Friedrich‐Wilhelms‐Universität Bonn
| | - Galina Balakirski
- Klinik und Poliklinik für Dermatologie und AllergologieUniversitätsklinikum der Rheinischen Friedrich‐Wilhelms‐Universität Bonn
| | - Lisa Marie Braun
- Klinik und Poliklinik für Dermatologie und AllergologieUniversitätsklinikum der Rheinischen Friedrich‐Wilhelms‐Universität Bonn
| | - Jörg Wenzel
- Klinik und Poliklinik für Dermatologie und AllergologieUniversitätsklinikum der Rheinischen Friedrich‐Wilhelms‐Universität Bonn
| | - Julia Altengarten
- Klinik und Poliklinik für Dermatologie und AllergologieUniversitätsklinikum der Rheinischen Friedrich‐Wilhelms‐Universität Bonn
| | - Thomas Bieber
- Klinik und Poliklinik für Dermatologie und AllergologieUniversitätsklinikum der Rheinischen Friedrich‐Wilhelms‐Universität Bonn
| |
Collapse
|
40
|
Sarles C, Valois A, Abed S, Boyé T, Fouet B, Morand JJ. [Pityriasis rubra pilaris: 3 cases with biologics]. Ann Dermatol Venereol 2019; 146:304-306. [PMID: 30929873 DOI: 10.1016/j.annder.2019.01.020] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/06/2018] [Revised: 07/21/2018] [Accepted: 01/23/2019] [Indexed: 01/12/2023]
Affiliation(s)
- C Sarles
- Service de dermatologie, hôpital d'instruction des armées, 83800 Toulon, France
| | - A Valois
- Service de dermatologie, hôpital d'instruction des armées, 83800 Toulon, France
| | - S Abed
- Service de dermatologie, hôpital d'instruction des armées, 83800 Toulon, France
| | - T Boyé
- Service de dermatologie, hôpital d'instruction des armées, 83800 Toulon, France
| | - B Fouet
- Service d'anatomopathologie, hôpital d'instruction des armées, 83800 Toulon, France
| | - J-J Morand
- Service de dermatologie, hôpital d'instruction des armées, 83800 Toulon, France.
| |
Collapse
|
41
|
Kromer C, Sabat R, Celis D, Mössner R. Systemische Therapien bei Pityriasis rubra pilaris: eine systematische Übersicht. J Dtsch Dermatol Ges 2019; 17:243-260. [DOI: 10.1111/ddg.13718_g] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2018] [Accepted: 06/29/2018] [Indexed: 11/30/2022]
Affiliation(s)
- Christian Kromer
- Klinik für DermatologieVenerologie und AllergologieUniversitätsmedizin Göttingen Göttingen Deutschland
| | - Robert Sabat
- Interdisiplinäre Gruppe für Molekulare Immunpathologie, Dermatologie/Medizinische Immunologie, Charité – Universitätsmedizin Berlin Berlin Deutschland
- Psoriasis Forschungs‐ und BehandlungsCentrum, Klinik für Dermatologie, Venerologie und Allergologie und Institut für Medizinische Immunologie, Charité – Universitätsmedizin Berlin Berlin Deutschland
| | - Daniel Celis
- Wirtschaftswissenschaftliche Fakultät, Universität Göttingen Göttingen Deutschland
| | - Rotraut Mössner
- Klinik für DermatologieVenerologie und AllergologieUniversitätsmedizin Göttingen Göttingen Deutschland
| |
Collapse
|
42
|
Kromer C, Sabat R, Celis D, Mössner R. Systemic therapies of pityriasis rubra pilaris: a systematic review. J Dtsch Dermatol Ges 2018; 17:243-259. [PMID: 30520557 DOI: 10.1111/ddg.13718] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/25/2018] [Accepted: 06/29/2018] [Indexed: 02/03/2023]
Abstract
Pityriasis rubra pilaris (PRP) is a rare papulosquamous disorder. Treatment is challenging; the armamentarium consists of topical corticosteroids, phototherapy, classic systemic treatments such as retinoids or immunosuppressive drugs, and most recently biologicals. However, the relative effectiveness of therapies is unclear. Our objective was to review the published literature on systemic treatment of PRP. A systematic review was conducted on PubMed and the Cochrane Library up to 5 September 2017. Studies evaluating any systemic treatments of PRP (except for historical treatments) were included. Overall, 182 studies met the predefined inclusion criteria, and reported on 475 patients and 652 courses of treatment. 42.0 % (225/514) of all patients treated with retinoids achieved an excellent response (isotretinoin: 61.1 % [102/167], etretinate: 47 % [54/115], and acitretin: 24.7 % [43/174]) compared to an excellent response rate of 33.1 % (53/160) with methotrexate. Therapy with biologicals was successful in 51.0 % of patients (71/133) (ustekinumab: 62.5 % [10/16], infliximab: 57.1 % [28/49], etanercept: 53.3 % [16/30], and adalimumab: 46.4 % [13/28]). This review balances effectiveness, side effects, experience, and drug costs in order to suggest a treatment regimen starting with isotretinoin as first-line, methotrexate as second-line and biologicals as third-line treatment for this difficult-to-treat dermatosis.
Collapse
Affiliation(s)
- Christian Kromer
- Department of Dermatology, Venereology, and Allergology, University Medical Centre, Göttingen, Germany
| | - Robert Sabat
- Interdisciplinary Group of Molecular Immunopathology, Dermatology/Medical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany.,Psoriasis Research and Treatment Center, Department of Dermatology and Allergy and Institute of Medical Immunology, Charité - Universitätsmedizin Berlin, Berlin, Germany
| | - Daniel Celis
- Faculty of Economic Sciences, Göttingen University, Göttingen, Germany
| | - Rotraut Mössner
- Department of Dermatology, Venereology, and Allergology, University Medical Centre, Göttingen, Germany
| |
Collapse
|
43
|
Pityriasis Rubra Pilaris With Extensive Follicular Acantholysis Resembling Pemphigus Vulgaris: A Case Report. Am J Dermatopathol 2018; 41:37-39. [PMID: 30045068 DOI: 10.1097/dad.0000000000001222] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/06/2023]
Abstract
Pityriasis rubra pilaris (PRP) is a rare, chronic, heterogeneous, papulosquamous inflammatory dermatosis of unknown etiology. Although erythematous scaly patches characterize the classic presentation of PRP, a broad range of clinical presentations has been reported. Histologically, PRP is characterized by psoriasiform acanthosis with alternating orthokeratosis and parakeratosis and rarely small acantholytic foci. In this article, we report a patient who presented with diffuse erythroderma and extensive acantholysis mimicking pemphigus vulgaris histologically.
Collapse
|
44
|
Hanfstingl K, Pekar-Lukacs A, Motz R, Guenova E, Hoetzenecker W. Successful Treatment of Pityriasis Rubra Pilaris with Ixekizumab. Case Rep Dermatol 2018; 10:97-100. [PMID: 29867429 PMCID: PMC5981592 DOI: 10.1159/000488902] [Citation(s) in RCA: 15] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/06/2018] [Accepted: 03/28/2018] [Indexed: 12/28/2022] Open
Abstract
Pityriasis rubra pilaris is an inflammatory dermatologic disorder of unknown cause and often confounded with psoriasis. It is characterised by hyperkeratotic follicular papules, scaly erythematous plaques, palmoplantar keratoderma, and a progression to generalised erythroderma. Here, we report the case of a 68-year-old man with pityriasis rubra pilaris, who was successfully treated with ixekizumab, an interleukin-17A inhibitor.
Collapse
Affiliation(s)
- Kathrin Hanfstingl
- Department of Dermatology, Kepler University Hospital Linz, Linz, Austria
| | | | - Reinhard Motz
- Department of Pathology, Kepler University Hospital Linz, Linz, Austria
| | - Emmanuella Guenova
- Department of Dermatology, University Hospital Zurich, Zurich, Switzerland
| | | |
Collapse
|